Albiglutide
CER-4-T2D
GSK · Phase n/r · Active, not recruiting · Enrollment 781430
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| SGLT-2i (Comparison 1) | T2D only | n/r | n/r | n/r | n/r |
| DPP-4i (Comparison 1) | T2D only | n/r | n/r | n/r | n/r |
| SGLT-2i (Comparison 2) | T2D only | n/r | n/r | n/r | n/r |
| GLP-1 RA (Comparison 2) | T2D only | n/r | n/r | n/r | n/r |
| GLP-1 RA (Comparison 3) | T2D only | n/r | n/r | n/r | n/r |
| DPP-4i (Comparison 3) | T2D only | n/r | n/r | n/r | n/r |
| SGLT-2i (Comparison 4) | T2D only | n/r | n/r | n/r | n/r |
| SU (Comparison 4) | T2D only | n/r | n/r | n/r | n/r |
| GLP-1 RA (Comparison 5) | T2D only | n/r | n/r | n/r | n/r |
| SU (Comparison 5) | T2D only | n/r | n/r | n/r | n/r |
| DPP-4i (Comparison 6) | T2D only | n/r | n/r | n/r | n/r |
| SU (Comparison 6) | T2D only | n/r | n/r | n/r | n/r |
| SGLT2i (Comparison 7) | T2D only | n/r | n/r | n/r | n/r |
| GLP-1 RA (Comparison 7) | T2D only | n/r | n/r | n/r | n/r |
| DPP-4i (Comparison 7) | T2D only | n/r | n/r | n/r | n/r |
| SU (Comparison 7) | T2D only | n/r | n/r | n/r | n/r |
| SGLT2i (Comparison 8) | T2D only | n/r | n/r | n/r | n/r |
| GLP-1 RA (Comparison 8) | T2D only | n/r | n/r | n/r | n/r |
| DPP-4i (Comparison 8) | T2D only | n/r | n/r | n/r | n/r |